MAPT and Parkinson disease: The most well established markers for the detection and monitoring of the preclinical and clinical stages of Alzheimer’s disease (AD) include cerebrospinal fluid (CSF) measures of Aβ42, total tau (t-tau), and phospho-tau (p-tau) [5], while the most promising for the diagnosis and monitoring of the progression of Parkinson’s disease (PD) is probably the assay of alpha-synuclein [6].